238 related articles for article (PubMed ID: 31181890)
1. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
[TBL] [Abstract][Full Text] [Related]
2. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
3. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
4. Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.
Zhang M; Ye J; Xie Z; Wang Y; Ma W; Kang F; Yang W; Wang J; Chen X
Mol Pharm; 2022 May; 19(5):1548-1556. PubMed ID: 35357154
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
[TBL] [Abstract][Full Text] [Related]
6. A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.
Uehara T; Yokoyama M; Suzuki H; Hanaoka H; Arano Y
Clin Cancer Res; 2018 Jul; 24(14):3309-3316. PubMed ID: 29666303
[No Abstract] [Full Text] [Related]
7. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.
Zhang M; Ye J; Xie Z; Yan Y; Wang J; Chen X
Bioconjug Chem; 2021 Sep; 32(9):2108-2116. PubMed ID: 34486879
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
[TBL] [Abstract][Full Text] [Related]
11. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK.
Trachsel B; Valpreda G; Lutz A; Schibli R; Mu L; Béhé M
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):21. PubMed ID: 37665477
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
13. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
15. Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios.
Suzuki H; Kise S; Kaizuka Y; Watanabe R; Sugawa T; Furukawa T; Fujii H; Uehara T
ACS Omega; 2021 Aug; 6(33):21556-21562. PubMed ID: 34471758
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [
Li J; Rawson J; Chea J; Tang W; Miao L; Sui F; Li L; Poku E; Shively JE; Kandeel F
Sci Rep; 2019 Apr; 9(1):5705. PubMed ID: 30952975
[TBL] [Abstract][Full Text] [Related]
18. Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients.
Buitinga M; Jansen T; van der Kroon I; Woliner-van der Weg W; Boss M; Janssen M; Aarntzen E; Béhé M; Wild D; Visser E; Brom M; Gotthardt M
J Nucl Med; 2019 Jun; 60(6):812-816. PubMed ID: 30504139
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
20. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]